Rare Disease

Today, Dermatology Times recognizes Rare Disease Day in an effort to amplify the voices of the over 300 million individuals affected by rare diseases.

Patients treated with dupilumab showed significant reductions in disease severity, itch, and corticosteroid use.

The initiative, created by Quoin, promotes educational resources and study updates about the rare disease.

Pilot and research grants may be awarded to research on keratinocyte biology and differentiation, genetics, biology of skin inflammation, itch, or other ichthyosis-related areas.

In an interview with Dermatology Times, Del Rosso shared the latest in the treatment landscape for patients with Darier disease.

Del Rosso outlined new and off-label therapies for the disease that he shared in his presentation at Winter Clinical Miami.

In an interview with Dermatology Times, Del Rosso gave insight on off-label therapies that could be used to treat granuloma annulare.

QRX003 mimics the LEKTI protein to strengthen skin barriers and alleviate symptoms in patients with Netherton Syndrome.

Disease severity improved from severe to mild after just 6 weeks of twice daily dosage.

The results showed promising improvements in all endpoints with high patient satisfaction and no safety concerns.

The "whole body" study at Northwestern will be lead by Amy Paller, MD, begins soon.

Abeona's pz-cel has been granted a April 29, 2025, PDUFA date.

The nonsteroid 1% cream treatment demonstrated good response and tolerability in patients with PPP.

A new method using 2 single-guide RNA/Cas9 tools to target 3 specific COL7A1 gene segments with harmful mutations successfully removed up to 95% of those segments.

Researchers conducted an assessment of the Nationwide Emergency Department Sample to analyze frequency of visits attributed to young patients with DEB.

A systematic review of 31 studies found that patients with EBA responded well to rituximab with few adverse effects.

Oleogel-10 exhibited potential to alleviate the physical, emotional, and economic strain of dressing changes, according to a poster presented at the SPD's annual meeting.

The international study represents the most comprehensive analysis of Southeast Asian patients with CI to date and provides a detailed look into specific CI subtypes.

A recent study found the use of CO2 lasers significantly improved patient quality of life and disease symptoms in the long-term.

A recent study spotlights an opportunity for interdisciplinary collaboration between dermatologists and orthodontists.

Patients who responded to imsidolimab in GEMINI-1 and who moved into GEMINI-2 maintained clear or almost clear skin.

Chinese clinical researchers recently presented a unique case of JLIS manifesting as erythematous papules and infiltrative plaques on the nose and upper jaw, resembling rosacea.

The CRL indicates that the timing proposed for data submission would not allow enough time for the FDA to complete its review by the May 25 PDUFA date.

Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.

Joseph Zabinski, PhD, MEM, of OM1, shares insights at AAD into how artificial intelligence can mature and be a positive tool for disease detection.

The congenital ichthyosis session the 2024 AAD Annual Meeting covered real-world patient cases and treatments on the horizon.

Christopher Bunick, MD, PhD, provides tips for the general dermatologist to treat ichthyosis and shares data on TMB-001 in development for ichthyosis.

Click here to answer our poll on rare dermatologic diseases.

Today is Rare Disease Day. Here's a look back at news related to rare skin conditions over the past year.

This Rare Disease Day, Joseph Zabinski, PhD, MEM, of OM1, discusses the role of artificial intelligence in helping to detect rare dermatologic diseases.